Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients

Nearly all patients with end-stage renal disease develop hyperphosphatemia. These patients typically require oral phosphate binders for life-long phosphorus management, in addition to dietary restrictions and maintenance dialysis. Recently, niacin, a traditional antilipemic agent, drew attention as...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Sooyoung, Lee, Sukhyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206247/
https://www.ncbi.nlm.nih.gov/pubmed/25342908
http://dx.doi.org/10.2147/TCRM.S71559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206247/
https://www.ncbi.nlm.nih.gov/pubmed/25342908
http://dx.doi.org/10.2147/TCRM.S71559

Ejemplares similares